Company news

Xilio Therapeutics, Inc. news in 2022

Xilio Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12

November 22, 2022

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results

November 8, 2022

Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors

September 14, 2022

Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results

August 8, 2022

Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President

June 15, 2022

Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer

May 16, 2022

Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results

May 11, 2022

Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors

January 19, 2022

Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors

January 5, 2022

Decks in 2022